Dr. Wyatt receives a CIHR Early Career Investigator Award

Date Posted: 
2017-12-07

Dr. Alex Wyatt has been awarded a 2017 CIHR Early Career Investigator Award.  His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies. The funding partners are the Institute of Cancer Research and AstraZeneca Canada Inc., and the award is for $345,000 over 3 years.

Chemotherapy has historically been the most effective treatment for metastatic disease, but long-term survival has been a rarity. Recently, new drugs including immunotherapies are showing significant promise, but only a small proportion of patients respond to these treatments and there currently is no reliable way of predicting who the responders will be.

Dr. Wyatt established the groundwork for this project during the first three years of his faculty appointment, during which time he worked closely with clinical collaborators to develop a blood test that can identify tumor DNA present in a small blood sample. Preliminary work with this circulating tumor DNA (ctDNA) suggests that mutations detected in ctDNA accurately reflect cancer itself, meaning that a patient’s metastatic bladder cancer can be profiled without the need for a tissue biopsy (see Vandekerkhove et. al., Clin Cancer Res. 2017 Nov 1;23(21):6487-6497 PMID: 28760909).

His awarded project,"Circulating tumour DNA as a precision oncology tool for metastatic bladder cancer," will identify mutations in the ctDNA of hundreds of Canadians with metastatic bladder cancer that are being treated with chemotherapy or immunotherapy. His research team will determine which mutations can predict a patient’s subsequent response to treatment using our rare combination of cancer bioinformatics and clinical oncology. Success with this project will help explain why some metastatic bladder cancers are intrinsically responsive or resistant to the most commonly used therapies. Furthermore, Dr. Wyatt and his team will have developed a clinically-practical framework (requiring only a blood sample) that may ultimately help align patients with therapies which would provide the best chance of success.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Plaid for Dad

Plaid for Dad Fundraiser, June 14, 2019

Plaid for Dad is a workplace fundraiser for Prostate Cancer Canada, with online registration & fundraising leading up to Friday June 14th's "wear plaid to work" day. Visit the event website to register a team, join/fundraise for a team or buy plaid to wear on the day.      

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC takes place on Sunday June 16, 2019 in various locations across BC. Registration fees ($40) include a shirt and BBQ lunch, and are waived for those who raise over $150. Click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Friday, May 3, 2019

Dr. Mads Daugaard receives the St. Baldrick’s Foundation Robert J. Arceci Innovation Award

Dr. Daugaard
Thursday, April 18, 2019

Dr. Subramaniam joins UBC as Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design

Dr. Subramaniam
Monday, April 1, 2019

VPC's translational research profiled in UBC Faculty of Medicine News

Dr. Gleave at the VPC